An increased risk of secondary hematological malignancies in cancer patients receiving G-CSF is suggested, although this association has not been found consistently and might be also related to increased doses of chemotherapeutic agents with leukemogenic potential [19,22]. Here, CSF3 is linked to hematologic disorder.